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Background: Lung cancer (LC) is still the most common cause of cancer related deaths worldwide. Non-small cell
lung cancer (NSCLC) accounts for 85% of all LC cases but is not a single entity. It is now accepted that, apart from
the characteristic driver mutations, the unique molecular signatures of adeno- (AC) and squamous cell carcinomas
(SCC), the two most common NSCLC subtypes should be taken into consideration for their management.
Therapeutic interventions, however, frequently lead to chemotherapy resistance highlighting the need for in-depth
analysis of regulatory mechanisms of multidrug resistance to increase therapeutic efficiency.
Methods: Non-canonical Wnt5a and canonical Wnt7b and ABC transporter expressions were tested in primary
human LC (n = 90) resections of AC and SCC. To investigate drug transporter activity, a three dimensional (3D)
human lung aggregate tissue model was set up using differentiated primary human lung cell types. Following
modification of the canonical, beta-catenin dependent Wnt pathway or treatment with cisplatin, drug
transporter analysis was performed at mRNA, protein and functional level using qRT-PCR, immunohistochemistry,
immune-fluorescent staining and transport function analysis.
Results: Non-canonical Wnt5a is significantly up-regulated in SCC samples making the microenvironment different
from AC, where the beta-catenin dependent Wnt7b is more prominent. In primary cancer tissues ABCB1 and ABCG2
expression levels were different in the two NSCLC subtypes. Non-canonical rhWnt5a induced down-regulation of both
ABCB1 and ABCG2 transporters in the primary human lung aggregate tissue model recreating the SCC-like transporter
pattern. Inhibition of the beta-catenin or canonical Wnt pathway resulted in similar down-regulation of both ABC
transporter expression and function. In contrast, cisplatin, the frequently used adjuvant chemotherapeutic agent,
activated beta-catenin dependent signaling that lead to up-regulation of both ABCB1 and ABCG2 transporter
expression and activity.
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Conclusions: The difference in the Wnt microenvironment in AC and SCC leads to variations in ABC transporter
expression. Cisplatin via induction of canonical Wnt signaling up-regulates ABCB1 and ABCG2 drug transporters that
are not transporters for cisplatin itself but are transporters for drugs that are frequently used in combination therapy
with cisplatin modulating drug response.
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Despite of the alarming statistics of lung cancer in-
cidence and mortality rates, development of an all-
around successful therapy remains elusive. Partly, as
lung cancers (LC) are highly diverse and apart from
small (SCLC) and non-small cell lung cancers (NSCLC)
there are morphologically diverse subtypes that are
frequently mixed. Additionally, their clinical character-
istics and drug sensitivity also varies greatly. As there
are no available targeted therapies for each variation,
the treatment approaches are similar and the overall
prognoses are still grim.
The 5 year survival rate of NSCLC varies from 73% in
early detection (stage IA) to 3.7% at advanced metastatic
disease [1, 2]. At early stages of NSCLC surgery and
chemotherapy are still the choices of first line treatment
[3, 4], although targeted molecular therapies are now
more widely included in the treatment regimen. Tar-
geted therapies that can extend progression free and
overall survival are only available to a fraction of patients
as such approaches require the presence of mutations or
amplifications of specific genes most frequently KRAS,
EGFR or ALK [1, 5, 6].
Unfortunately, the majority of patients are presented
at advanced or even metastatic stage of the diseaseTable 1 List of gene specific primers used in qRT-PCR





human ABCB1 NM_000927 for-GCAGCTGGAAGACAAATACACAA
rev-CCCAACATCGTGCACATCA
human ABCG2 NM_004827 for-AACCTGGTCTCAACGCCATC
rev-GTCGCGGTGCTCCATTTATC
human ABCC1 NM_004996.3 for-GCTGGAGTGTGTGGGCAACT
rev-CTGAGGCTGTGCCTGGAGAT
human ABCC2 NM_000392 for-GCAAACTGTTCTGGTGTGGA
rev-CCAGCTCTATGGCTGCTAGA
human Wnt5a NM_003392 for-CCTGCTCCTGACCGTCC
rev-CAAAGCAACTCCTGGGCTTA
human Wnt7b NM_058238 for-GTCCTGTACGTGAAGCTCGG
rev-CGGAACTGGTACTGGCACTCwhere surgical resection is not an option. Cisplatin based
therapy can increase the survival rates in all stages but
chemotherapy resistance and disease recurrence remain
major issues. In metastatic disease, treatment is fre-
quently based on the combination therapies of cisplatin
or carboplatin with drugs such as paclitaxel, docetaxel,
gemcitabine and vinorelbine to increase efficacy com-
pared to single agent platinum therapy [7]. And although
the use of immune modulators (e.g. Nivolumab) has be-
come a promising route to effectively halt disease progres-
sion, their application in fast progressing tumor types
require further analysis including drug interaction studies
between small molecules and biological therapies [8].
Studies of influx and efflux mechanisms of drug trans-
porters might help to evaluate effectiveness of drugs in
therapy. In various studies ATP-binding cassette (ABC)
transporter family members, such as ABCB1 (MDR1 or
Pgp) and ABCG2 (BCRP1) are involved in drug resist-
ance [9, 10]. While cisplatin is not an ABCB1 or ABCG2
substrate [11, 12], association studies implicated ABCG2
as a predictive factor for poor clinical outcome of
advanced NSCLCs [13]. The link of ABCB1 to NSCLC
chemoresistance remained inconclusive [14–16], although
drugs like erlotinib, irinotecan etc. that are widely used in
combination therapy of NSCLC are ABCB1 and ABCG2
substrates [17, 18].
Interestingly, it has recently been shown that TCF/LEF
dependent signaling activates the ABCB1 promoter indi-
cating that beta-catenin dependent Wnt signaling [19] is
involved in ABCB1 expression [20] and therefore poten-
tially in chemoresistance [21, 22]. The highly complex
and evolutionarily conserved Wnt signaling pathway
controls many developmental and tissue maintenance
events via the canonical or beta-catenin dependent, and
two non-canonical pathways [19]. Previous studies have
shown that Wnt pathway, although rarely mutated, is
differentially regulated in LC subtypes. While beta-catenin
dependent signaling can be strongly down-regulated in
SCLC through over-expression of inhibitory genes differ-
ential activation of the beta-catenin dependent canonical
and Ca2+ dependent non-canonical Wnt pathways have
been reported in NSCLC subtypes of AC and SCC,
respectively [23, 24].
As resistance to chemotherapy is a major obstacle to
successful treatment of lung cancer and resistance is
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porters, we have theorized that the generally applied
platinum-based therapy might be able to affect drug
transporter expression and activity via modulation of
Wnt signaling. Thus, the aim of the present study was to
test the following hypotheses: (i) Expression of ABC
transporters are different in AC and SCC subtypes of
NSCLC patients due to the highly diverse Wnt micro-
environment; and (ii) Differential expression and func-
tionality of ABCB1 and ABCG2 are directly regulated by
cisplatin modified Wnt signaling leading to altered re-
sponse to second in line drugs.
Methods
Ethical Statement
Lung tissue samples were collected at the Department of
Surgery coordinated by the Department of Pathology,
University of Pecs, Hungary. The project was approved
by the Ethical Committee of the University of Pecs
(ETT-TUKEB 366/2015). Patients had given written
consent to provide samples for research purposes. All
collected samples were treated anonymously.
Human lung samples
A total of 90 patient samples were processed, 76 adeno-
carcinomas and 14 squamous cell carcinomas that were
collected at the Department of Surgery, assessed by a
certified lung pathologist based on WHO guidelines.
Cell culture
Primary human small airway epithelial cells (SAEC), nor-
mal human lung fibroblasts cells (NHLF) and normal
human lung microvascular endothelial cells (HMVEC-L)
were cultured according to the manufacturers’ re-
commendations (Lonza, Basel, Switzerland). Briefly, cells
were thawed and cultured as monolayer in Small Airway
Growth Medium (SAGM), Fibroblast Growth Medium
(FGM-2) and Endothelial Growth Medium (EGM-2)
respectively at 37 °C in humidified atmosphere contain-
ing 5% CO2. A549 lung adenocarcinoma were grown in
complete DMEM containing 10% FBS and H520 lung
squamous carcinoma cells (American Type Culture Col-
lection, Rockville, MD) were cultured in complete RPMI
containing 10% FBS at 37 °C in humidified atmosphere
containing 5% CO2. Trypan blue dye exclusion test was
used to assess cell viability in all culture types.
Drugs used in the experiments
Cisplatin, Paclitaxel, Doxorubicin and Gemcitabine were
all purchased from Selleck Chemicals (Selleck Chemicals,
Houston, USA). Treatments were conducted at final con-
centrations as follows cisplatin of 29.7 μM [25], paclitaxel
of 100 nM [26], doxorubicin of 100 nM [26] and gemcita-
bine of 100 nM [26].Cellular fractionation and Western-blot analysis
A549 lung adenocarcinoma cells (American Type Culture
Collection, Rockville, MD) were grown in complete
DMEM until reaching 70% confluence. Cells were treated
for 3 h with cisplatin (Selleck Chemicals, Houston, USA)
at final concentration of 29.7 μM [25]. All experiments
were done in triplicates. After treatment, cells were
rinsed with PBS and collected with trypsin, then pro-
ceeded with protocol for cell compartment isolation.
A549 cells were used between passage number 8 to 10
and epithelial characteristics were proved by cytokera-
tin positivity. All the cell cultures were regularly tested
for mycoplasma infection [27].
3D lung aggregate cultures
Aggregates containing NHLF, SAEC and HMVEC-L cells
were mixed at 4:3:3 ratio, and dispensed onto poly-
HEMA-coated (final concentration 20 mg/ml) 96-well
plates (TPP, Sigma-Aldrich, St. Louis, USA) as described
earlier [28]. The plates were centrifuged for 10 min at
600 x g at 4 °C. The final number of cells/well was
30.000. Aggregates were grown in SAGM/EGM-2/FGM-
2 media at 2:2:1 ratio. After 24 h 3D aggregates were
transferred on a 24 well plate (also coated with poly-
HEMA) and treated with recombinant human Wnt5a at
final concentration of 1 μg/ml for 72 h (Chinese
Hamster Ovary Cell Line, CHO-derived Gln38-Lys380)
(R&D Systems, Minneapolis, USA) [23], cisplatin
(Selleck Chemicals, Houston, USA) (29.7 μM for 72 h)
[25], IWR-1 (Sigma Aldrich, St. Louis, USA) (1 μM for
3 h) [23] and LiCl (Sigma Aldrich, St. Louis, USA)
(10 mM for 3 h) [29]. Upon treatment they were col-
lected in RA1 Buffer Solution for RNA isolation, into
cryostat embedding medium for dissection or used for
drug transporter functional test.
RNA isolation, cDNA synthesis and qRT-PCR
3D aggregates were collected in RA1 Buffer Solution
then on-column RNA isolation was performed according
to the manufacturers’ protocol (NucleoSpinII RNA isola-
tion kit, Macherey-Nagel, Düren, Germany). Total RNA
from frozen human lung samples was isolated using TRI
Reagent (Invitrogen, Thermo Fisher Scientific, Waltham,
USA) with an additional DNase (Sigma-Aldrich, St Louis,
USA) treatment. RNA concentration was measured
using Nanodrop technology (Thermo Fisher Scientific,
Waltham, USA).
cDNA synthesis was performed using random hex-
amer primers of the high capacity RNA to cDNA kit
(Thermo Fisher Scientific, Waltham, USA) according to
the manufacturers’ protocol.
SYBRGreen (Bioline, London, UK) real-time qRT-PCR
reaction (Table 1) was set up using StepOne and StepOne
Plus instruments (Thermo Fisher Scientific, Waltham,
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Ct values below 22.5 were used for further evaluation. The
relative quantities of different drug-transporters were cal-
culated using the 2-ddCt method. The reference gene was
beta-actin for all the samples.
Fluorescent staining and immunohistochemistry
Sections of 3D aggregate co-cultures were sectioned fro-
zen and fixed with either acetone or 4% PFA (paraformal-
dehyde) solution (depending on the primary antibody
used), and then stained by standard staining procedure.
Briefly, blocking was done with 5% BSA/PBS solution;
primary antibodies were diluted in the blocking solution
and incubated for 1 h at room temperature. After washing
the slides in PBS three times for 5 min, secondary anti-
body was applied for 45 min. Slides were then washed and
the nuclei were stained using TO-PRO-3 (Thermo Fisher
Scientific, Waltham, USA) in 1:1000 dilutions for 15 min.
Slides were washed again and covered with Vectashield
(Vector Laboratories, Burlingame, CA, USA) solution.
Primary antibodies of mouse monoclonal anti human
beta-catenin (E-5 clone, sc-7963, SantaCruz Biotechnol-
ogy, Dallas, TX, USA) were diluted 1:50, while the rabbit
monoclonal anti human phospho-beta-catenin (Ser675)
(4176S, Cell Signaling Technology, Danvers, USA)
antibody was used in 1:100 dilutions. Secondary anti-
bodies were AlexaFluor-488 conjugated anti-rabbit
and anti-mouse IgG antibodies from Thermo Fisher
Scientific (Waltham, USA) diluted 1:200. The pictures
were taken with Zeiss LSM 710 confocal microscope
(Zeiss, Oberkochen, Germany), always first adjusting
the parameters to the secondary antibody control and
then inspecting the actual slides using the same set-
tings. Images were evaluated using Fiji [30].
Immunohystochemical staining of ABC transporters and
Wnt ligands
Primary lung tissue and 3D co-cultures sections were cut
using Leica CM1950 cryostat (Leica, Wetzlar, Germany)
then fixed and stained with a routine IHC staining proced-
ure using Vision Biosystems bond™ automated immunos-
tainer (Leica, Wetzlar, Germany). Primary antibody of
mouse monoclonal anti-human ABCG2 (CD338, clone
5D3, BD Biosciences, San Jose, USA) was used in 1:50
dilution and rabbit monoclonal anti-human ABCB1 (1:50,
clone D3H1Q, Cell Signaling Technology, Danvers, USA).
Rat monoclonal anti-human Wnt5a (clone 442625) and
goat polyclonal anti-human Wnt7b antibodies were pur-
chased from R&D Systems, (Minneapolis, USA) and used
in 1:50 dilutions.
Functionality test of drug transporters
All experiments were done using the “eFluxx-ID® Green
multidrug resistance assay kit” (ENZO, Enzo Life Sciences,Farmingdale, New York, USA) according to the manufac-
turers’ protocol. Briefly, 3D aggregates were enzymatically
digested using Accumax solution (Sigma Aldrich, St.
Louis, USA) and single cell suspension were mixed with
diluted drug transporter inhibitor molecules, incubated
for 5 min at 37 °C, then all samples were incubated with
diluted eFluxx-ID® Green dye for 30 min at 37 °C. After
30 min, propidium-iodide was added to all sample tubes
and were measured immediately with FACS Canto II flow
cytometer (BD, Biosciences, Immunocytometry Systems,
Erembodegen, Belgium). Appropriated controls (stained
and unstained) were included into procedure. The results
are calculated as multidrug resistance (MDR) activity
factor values (MAF).
Cell compartment fractionation and Western-blotting
Cell compartment factions were obtained using Qpro-
teome® Cell Compartment Kit (Qiagen, Hileden, Germany)
according to the manufacturer’s recommendation. Cell
compartment protein fractions were acetone precipitated.
Protein content was then measured using Protein Assay Kit
measured with Qubit® fluorometer (Thermo Fisher
Scientific, Waltham, USA). Samples were mixed with 4×
Laemmli sample buffer (BIO-RAD Laboratories, Hercules,
California, USA) and heated to 90 °C for 5 min. SDS-
electrophoresis was performed using Mini-Protean TGX™
Precast Gels (BIO-RAD Laboratories, Hercules, California,
USA), at 125 mA current. Blotting was done for 3 h at
140 V with nitrocellulose membrane (GE Healthcare Life
Sciences, Little Chalfont, UK). The membranes were
blocked for 1 h using 5% milk powder in PBS solution. The
primary antibody was rabbit anti-human beta-catenin
(clone D10A8, Cell Signaling Technology, Danvers, USA),
rabbit anti-human phospho-beta-catenin (clone D2F1, Cell
Signaling Technology, Danvers, USA) in 1:1000 dilution
and mouse anti-human beta-actin (clone AC-74, Sigma-
Aldrich, St. Louis, USA) in 1:2000 overnight. Secondary
antibody was goat anti-rabbit and anti-mouse IgG-HRP
conjugate (BIO-RAD Laboratories, Hercules, California,
USA) in 1:1000 dilution for 1 h. The proteins were detected
using SuperSignal West Femto Maximum Sensitivity
Substrate (Thermo Fisher Scientific, Waltham, USA) and
documented with ImageQuant LAS4000 CCD camera sys-
tem (Fujifilm, GE Healthcare Life Science, Little Chalfont,
UK). Pictures were processed using Fiji [30].
Statistical analysis
Kolmogorov-Smirnov test was used to determine the
distribution of variables. Nonparametric tests were applied
for the variables with no Gaussian distribution. Kruskal-
Wallis test was used for effective differences among all
groups. For comparing differences between groups in con-
tinuous variables with non-normal distribution Mann–
Whitney-U tests were appropriate. Spearman correlation
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between two continuous random variables. SPSS 22.0
package for Windows (SPSS Inc., Chicago, IL, USA) was
applied for all statistical analyses. Differences were consid-
ered statistically significant at *P < 0.05, **P < 0.01 and
***P < 0.001.
Results
ABCB1 and ABCG2 transporters are differentially
expressed in primary AC and SCC
mRNA levels of ABCB1 and ABCG2 transporters were
investigated in 90 resected, primary human lung AC and
SCC tissue samples by qRT-PCR and immunohis-
tochemistry (Fig. 1a, c). Data revealed significant differ-
ences in both ABCB1 and ABCG2 mRNA expression
levels messages being higher in AC compared to SCC
(Fig. 1a). Reflecting mRNA, ABCB1 protein was strongly
expressed in AC but not in SCC (Fig. 1c) while ABCG2
levels were barely detectable in AC and non-detectable
in SCC samples (Additional file 1: Figure S1). As the
Wnt molecular background of AC and SCC differ
(Fig. 1b, d), understanding any connections between theC)
A) B
D)
Fig. 1 Drug transporter and Wnt microenvironment analysis of primary hu
ABCG2 drug transporters and b) non-canonical Wnt5a and canonical Wnt7
to normal, healthy lung tissue. n = 76 for AC, and n = 14 for SCC. Data are p
SCC of c) ABCB1 drug transporter protein staining (n = 5 each) and d) Wnt
bar 100 μmunderlying molecular differences in the Wnt pathways
and drug transporter induced chemoresistance can only
become possible if in vitro studies are available. To
model the microenvironment of the pulmonary tissue,
3D aggregate cultures were set up using primary human
lung cell types HMVEC-L, SAEC and NHLF derived
from commercially available healthy human donor tis-
sues. Analysis of the aggregates revealed that ABCB1
and ABCG2 drug transporters at message levels were
similar to that of primary healthy human lungs, and
both transporters were expressed as active proteins
(Additional file 2: Figure S2) making the model suit-
able for drug transporter regulation studies.
Wnt dependent differential regulation of drug transporter
expression
As differences were detected in beta-catenin dependent
canonical (Wnt7b) and Ca2+ dependent non-canonical
Wnt5a expression in AC and SCC [23] (Fig. 1b, d),
respectively, the AC-like canonical Wnt pathway activa-
tion was mimicked in the lung tissue aggregate by
stimulating the canonical Wnt signaling pathway using)
man AC and SCC samples. Relative mRNA expression of a) ABCB1 and
b in primary human AC and SCC samples. mRNA expression is relative
resented as mean ± SEM. Immunohistochemistry of primary AC and
5a ligand protein staining (n = 5 each). Magnification is 20×, scale
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activator of the beta-catenin pathway. As non-canonical
pathway signals suppress the beta-catenin driven gene
transcription, the SCC dependent Wnt microenviron-
ment was simulated by the beta-catenin pathway inhibi-
tor IWR (1 μM) [23] as well as treating the cultures with
rhWnt5a (1 μg/ml final concentration).
Chemical modification of Wnt signaling revealed that
inhibition of beta-catenin down-regulates both ABCB1
and ABCG2 (Fig. 2a), while activation of beta-catenin
significantly up-regulates the expression of both trans-
porters (Fig. 2a). Treatment of lung aggregate cultures
with rhWnt5a reduced ABCG2 mRNA levels compared
to untreated controls but had no effect on ABCB1. As
ABCG2 expression in primary SCC is much lower than
ABCB1 (Fig. 2b), treatment of lung aggregate cultures
with rhWnt5a induced changes in drug transporter
pattern in vitro that was highly similar to what was de-
tected in primary cancer samples of squamous histology.
Based on the above data we concluded that alterations
in the Wnt microenvironment differentially affects both
ABCB1 and ABCG2 expression.
Cisplatin modulates the Wnt microenvironment leading
to altered drug transporter activity
Cisplatin induced multidrug resistance [32] is still a major
problem in cancer therapy. While cisplatin up-regulates
ABCC1 and ABCC2 (Additional file 3: Figure S3)
encoding multidrug resistance-associated protein 1 and 2
(MRP1 and MRP2), there is no explanation why cisplatin
would affect ABCB1 or ABCG2 while not being a sub-
strate for either transporters itself [11, 12]. To investigate,
3D lung aggregates were treated with 29.7 μM cisplatinA)
Fig. 2 Wnt dependent differential regulation of drug transporters. Relat
HMVEC-L-NHLF-SAEC aggregates treated with canonical Wnt pathway i
is compared to untreated controls, n = 3 b) ABCB1 and ABCG2 express
recombinant human Wnt5a treatment shows similar pattern that SCC p
to untreated controls, n = 3, mRNA expression of primary SCC samplesfor 72 h, then the canonical Wnt7b and the non-canonical
Wnt5a message levels were measured by qRT-PCR
(Fig. 3a). Cisplatin down-regulated Wnt5a (Fig. 3a), it also
significantly increased the expression of the canonical
Wnt7b. Simultaneously, both ABCB1 and ABCG2 mRNA
levels (Fig. 3b) increased. The above data are in agreement
shown in Fig. 2 where ABCB1 and ABCG2 up-regulation
was detected in the presence of beta-catenin dependent
Wnt pathway activation while inhibition of the same path-
way resulted in reduced transporter expression (Fig. 2).
To demonstrate that the beta-catenin pathway was
activated by cisplatin, control and cisplatin treated 3D
aggregate culture sections were stained for beta-catenin
and phospho-Ser675-beta-catenin levels [33, 34].
Stabilization and therefore significant increase of
beta-catenin protein as well as activated phospho-
Ser675-beta-catenin was measured in samples following
cisplatin treatment (Fig. 3c). Interestingly, Western blot
analysis revealed a cisplatin induced cell membrane
localization of active beta-catenin (Fig. 3d). To test
whether modulation of beta-catenin activity correlates
with transporter activity, a functional assay was performed
(Fig. 3e). Although inhibition of the canonical Wnt
pathway by IWR significantly suppressed ABCB1 but had
no effect on ABCG2 activity, activation of the canonical
pathway by 10 mM LiCl slightly but not significantly in-
creased activity of both ABCB1 and ABCG2 transporters
compared to untreated controls (Fig. 3e).
Induction of ABC transporter mRNA levels by drugs used
in combination therapy
To test whether paclitaxel, doxorubicin and gemcitabine
drugs that are frequently applied in combination therapyB)
ive mRNA expression of a) ABCB1 and ABCG2 expression in 3D
nhibitor, IWR and inducer, LiCl for 3 h. mRNA of treated samples
ion in 3D HMVEC-L-NHLF-SAEC co-culture aggregates following
rimary samples. mRNA expression of treated samples is compared
is compared to normal lung tissue
Fig. 3 Effects of cisplatin treatment. Relative mRNA expression of a) Wnt5a and Wnt7b in cisplatin treated 3D HMVEC-L-NHLF-SAEC co-culture
aggregates. mRNA expression of treated samples is compared to untreated controls, n = 3 b) ABCB1 and ABCG2 in cisplatin treated (29.7 μM, 3 h)
3D HMVEC-L-NHLF-SAEC co-culture aggregates. mRNA expression is normalized to beta-actin, n = 3 c) Representative images of Ser675
phosphorylated beta-catenin immune-fluorescent staining in control and cisplatin treated 3D HMVEC-L-NHLF-SAEC aggregates. Fluorescence intensity
are representations of three different experiments as mean ± SEM. Scale bar 50 μm, magnification 63×. d) Western-blot analysis and densitometric
quantification of Ser675 phosphorylated beta-catenin and beta-catenin proteins in different cell fractions of control and cisplatin treated A549 lung
adenocarcinoma cell cultures, n = 3 e) functional activity of ABCB1 and ABCG2 drug transporters in 3D co-culture aggregates following canonical Wnt
pathway inhibitor, IWR and inducer, LiCl treatment. Data are presented as mean ± SEM of multidrug resistance activity factor values (MAF), n = 3. MAF
values≤ 20 are considered as MDR negative
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were created using primary human lung fibroblasts
(NHLF) and the adenocarcinoma cell line A549 or the
squamous cell carcinoma cell line H520. Tissue aggre-
gates then were treated with the above drugs at concen-
trations of 100 nM, respectively, for 48 h. qRT-PCR tests
revealed that gemcitabine triggered a significant increase
in ABCB1 and ABCC2 expression both in adeno and
squamous cell carcinoma tissues (Fig. 4a, b) while pacli-
taxel and doxorubicin differentially initiated drug trans-
porter transcription (Fig. 4a, b). Interestingly, while none
of the above drugs increased ABCC1 transporter mRNA
levels in adeno- (A549) or squamous (H520) carcinoma
cell line aggregate tissues, ABCC2 were significantly up-
regulated by all paclitaxel, doxorubicin and gemcitabine
but only in adenocarcinoma cell line (A549) containing
aggregate tissues (Fig. 4a, b).
Discussion
Lung cancers metastasize rapidly and often become in-
operable by the time of diagnosis. Cisplatin is the
chemotherapeutic drug that is still used in mono- or
combination therapies. Resistance to platinum agents,
however, invariably develops. The developing multidrug
resistance has been characterized as a multifactorial
process [35] but the regulatory mechanisms leading to
drug resistance are still not completely clear.
Our data revealed that ABCB1 and ABCG2 drug
transporters are differentially expressed in NSCLC sub-
types AC and SCC where Wnt signaling pathway activity
is also different. Using a 3D lung tissue model system it
was revealed that treatment of lung tissue with cisplatin
up-regulates the multidrug resistance associated protein
encoding ABCC1 and ABCC2 genes and via modulation
of the canonical and non-canonical Wnt pathways
increases ABCB1 and ABCG2 transporter expressionA)
Fig. 4 Effects of paclitaxel, doxorubicin and gemcitabine treatment. Relativ
following treatment of a) 3D co-culture aggregates of adenocarcinoma cel
cell carcinoma cell line H520 and NHLF; with 100 nM paclitaxel, 100 nM do
normalized to beta-actin. Data are presented as mean ± SEM, n = 3regardless of the fact that cisplatin is not a substrate for
the latter two efflux transporters [11, 12]. Inevitably,
substrate specificity can also change due to mutations in
drug transporter sequences [36] during disease progres-
sion. The present report provides an additional layer to
the already recognized complexity of drug resistance
highlighting the variable tissue microenvironment as a
regulatory factor in the process. It has also become clear
from the study that the characteristic and rarely mutated
Wnt microenvironments in lung cancer subtypes can be
mimicked and investigated in vitro. We have shown that
specific drug transporter expression is characteristic to
NSCLC subtypes but cisplatin can change the character-
istically non-canonical (Wnt5a) microenvironment of
SCC by activating the beta-catenin dependent route
leading to ABCB1 and ABCG2 up-regulation. As cis-
platin increased the canonical Wnt7b in the study,
increase of ABCB1 and ABCG2 perhaps is not surpris-
ing as previous studies have also demonstrated beta-
catenin dependent induction of ABCB1 [37, 38] in breast
cancer [39, 40] and ABCG2 in colon cancer [41]. If beta-
catenin was knocked down in breast cancer cells, che-
mosensitivity increased to doxorubicin and etoposide
[39, 40]. In our study treatment with cisplatin triggered
beta-catenin localization to the cellular membrane. As
beta catenin is a dual function protein, regulating not just
gene transcription in the canonical Wnt pathway but the
coordination of cell-cell adhesion, such observation might
bear additional importance. For efflux transporters to
work efficiently, they need to form a functionally active
complex [42–44]. If membrane structures e.g. beta-
catenin-E-cadherin can stabilize lipid rafts [45] to facilitate
the assembly of active drug transporter complexes, then
cisplatin can increase drug efflux and lower intracellular
anti-cancer drug levels in such a way that gene transcrip-
tion is not even involved in the process.B)
e mRNA expression of ABCB1, ABCG2, ABCC1 and ABCC2 were studied
l line A549 and NHLF; and b) 3D co-culture aggregates of squamous
xorubicin, 100 nM gemcitabine for 48 h. mRNA expression was
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is normally associated with E-cadherin binding and a
more differentiated epithelial phenotype. Interestingly,
ABCG2 can bind to the E-box promoter region of CDH1
(E-cadherin) regulating E-cadherin expression [46]. Low
levels of ABCG2 that was detected in resections of
primary tumors therefore can be considered as part of the
dedifferentiation process leading to low E-cadherin levels
and loosened tight junction interactions facilitating cellu-
lar migration that is necessary for tumor progression.
Despite extensive studies, the precise biochemical
mechanism of cisplatin induced modification of Wnt
pathway activity that leads to altered ABC transporter
expression and function is still not fully understood.
Connection to epigenetic modification and Wnt pathway
activation has been demonstrated in the literature not
just for cisplatin [47–49] but for other drugs including
paclitaxel, doxorubicin and gemcitabine [50, 51]. Further
studies, however, needed to reveal the step-by-step
biochemical mechanism and to identify molecular tar-
gets for intervention. This is particularly important as
the clinical consequences are far reaching. Erlotinib and
irinotecan are ABCB1 substrates while topotecan, irino-
tecan and tyrosine kinase inhibitors gefitinib and erloti-
nib are reported substrates of ABCG2 [52]. ABCG2 can
also transport for example doxorubicin [53] which is
used to treat brain metastasis of AC-NSCLCs [54].
Conclusion
Drug transporters are actively involved in a complex regu-
latory process of drug sensitivity and resistance that is
intertwined with epigenetic regulation of Wnt signaling.
The present study using resected tissues of primary
NSCLC subtypes and an in vitro tissue aggregate model of
the lung has provided the following information: a)
ABCB1 and ABCG2 drug transporters are expressed dif-
ferentially in AC and SCC tissues, b) drug transporter
transcription is affected differentially by cisplatin, pacli-
taxel, doxorubicin and gemcitabine, and c) and apart from
cisplatin, none of the studied drugs increased ABCC1
message levels indicating that in vitro determination of
recommended drug administration sequences can be de-
termined to aid more favorable clinical outcome.
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Additional file 1: Figure S1. ABCG2 and Wnt7b immunohistochemistry
images of primary adeno (AC) and squamous cell carcinoma (SCC) tissues.
Representative images of ABCG2 (B) and Wnt7b (B) immunochemistry of
primary AC and SCC tissues (n= 5, each). Scale bar is 100 μm at 20×
magnification and 50 μm at 40× magnification images. (DOCX 26321 kb)
Additional file 2: Figure S2. Establishing a 3D lung tissue aggregate
co-culture to model drug transporter expression and activity. Relative
mRNA expression of ABCB1 and ABCG2 drug transporters in A) 2D
monocultures, 3D co-culture aggregates (NS: NHLF-SAEC, HNS:HMVEC-L-NHLF-SAEC), B) in 3D co-culture aggregate (HNS: HMVEC-L-
NHLF-SAEC) and normal, healthy lung tissue. mRNA expression is relative
to beta-actin. In 2D cultures drug transporter expressions are much lower
than in the controls. These expression levels increase in 3D culture
conditions and all three cell types are needed to become similar to
normal lung tissue expression levels. Data are presented as mean ± SEM,
n = 3 C) representative image of ABCG2 protein expression in 3D co-culture
aggregate (HNS: HMVEC-L-NHLF-SAEC), scale bar 50 μm, magnification; D)
functional activity of ABCB1 and ABCG2 drug transporters in 3D HMVEC-L-
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Additional file 3: Figure S3. Effects of cisplatin in 3D lung tissue tumor
cell line aggregates. Relative mRNA expression of ABCC1 and ABCC2
drug transporters of cisplatin treatment of 3D co-culture aggregates
of adenocarcinoma cell line A549-NHLF (A) and (B); 3D co-culture
aggregates of squamous cell line H520-NHLF (C) and (D). Data are
presented as mean±SEM, n=3. (DOCX 55 kb)
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